SCHEMBL9865726

SCHEMBL9865726

Cc1ccc(SCCN=C(NCCCc2c[nH]cn2)NC(=O)c2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.47
ALDH1A1 P00352 3/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
SCN5A Q14524 6/20 0.43
SCN2A Q99250 6/20 0.43
HRH4 Q9H3N8 3/20 0.40
PKM P14618 1/20 0.40
KMT2A Q03164 1/20 0.40
HRH2 P25021 2/20 0.39
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.36
RECQL P46063 1/20 0.36
KDM4E B2RXH2 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9865721 1.00 HPGD (0.47) HPGDALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL9865876 0.96 HPGD (0.46) HPGDALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL9865867 0.96 HPGD (0.46) HPGDALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL9865881 0.94 HPGD (0.46) HPGDALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL9866763 0.94 NPC1 (0.42) HPGDALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL9867435 0.94 NPC1 (0.42) HPGDALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL9865732 0.93 HPGD (0.52) HPGDALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL9865207 0.91 NPC1 (0.37) HPGDALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL9866485 0.89 HRH4 (0.42) HPGDALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL10369046 0.89 HRH4 (0.42) HPGDALDH1A1CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5021431-A H-1 antagonist, h-2 agonist for treating hypertension, cardiac disease or arterial occlusion HEUMANN PHARMA GMBH & CO. (DE) 1991-06-04 US disclosed
EP-0199845-B1 IMIDAZOLYLALKYLGUANIDIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM HEUMANN PHARMA GMBH & CO (DE) 1990-08-01 EP disclosed
EP-0199845-A1 Imidazolylalkylguanidin derivatives, process for their preparation and pharmaceutical compositions containing them HEUMANN PHARMA GMBH & CO (DE) 1986-11-05 EP disclosed